Risk of Cancer in Connective Tissue Diseases in Northeastern Italy over 15 Years.
Sjogren’s syndrome
cancer
connective tissue diseases
lymphoma
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
06
06
2022
revised:
08
07
2022
accepted:
20
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
To evaluate cancer risk among individuals with connective tissue disease (CTD) in Friuli Venezia Giulia, northern Italy. A population-based cohort study was conducted based on data from health records available in the regional healthcare database. Demographic characteristics, hospital discharges, exemption from medical charges, drug prescriptions, were individually matched with data from the population-based cancer registry. Cancer risk was assessed in people diagnosed with the following diseases: systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), systemic sclerosis (SSc), polymyositis (PM), and dermatomyositis (DM). In all, 2504 patients were followed for a total of 18,006 person-years (median follow-up: 6.8 years). After 5 and 10 years of follow-up, the cumulative cancer incidence was 2.6% and 8.5%, respectively. The most common cancers were breast ( The incidence of NHL was higher among patients with SS and SLE. Careful surveillance for hematological malignancies in these patients is recommended.
Identifiants
pubmed: 35893361
pii: jcm11154272
doi: 10.3390/jcm11154272
pmc: PMC9332163
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Clin Rheumatol. 2011 May;30(5):665-72
pubmed: 21072553
Rheumatology (Oxford). 2021 Jun 18;60(6):2615-2628
pubmed: 33599244
J Clin Med. 2020 Aug 12;9(8):
pubmed: 32806710
J Rheumatol. 2008 Jan;35(1):100-5
pubmed: 17937462
Arthritis Rheum. 2006 Mar;54(3):692-701
pubmed: 16508929
Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101472
pubmed: 32029389
Ann Rheum Dis. 2014 Jan;73(1):138-42
pubmed: 23303389
Oncology. 2013;85(2):117-21
pubmed: 23887245
Autoimmun Rev. 2017 Oct;16(10):1049-1057
pubmed: 28778707
Front Immunol. 2020 Oct 19;11:594096
pubmed: 33193443
Clin Exp Rheumatol. 2018 May-Jun;36 Suppl 112(3):150-156
pubmed: 30156548
Autoimmun Rev. 2014 Jul;13(7):730-5
pubmed: 24657969
J Rheumatol. 2015 Feb;42(2):282-91
pubmed: 25448790
Blood. 2008 Apr 15;111(8):4029-38
pubmed: 18263783
J Intern Med. 2015 Oct;278(4):369-95
pubmed: 26212387
Oncoimmunology. 2019 Mar 24;8(6):e1588084
pubmed: 31069155
Int J Cancer. 2011 Jul 15;129(2):460-6
pubmed: 20853323
Scand J Rheumatol. 2002;31(2):66-71
pubmed: 12109649
Cancer. 1953 Nov;6(6):1147-58
pubmed: 13106829
Semin Cancer Biol. 2020 Aug;64:114-121
pubmed: 31181268
Curr Opin Rheumatol. 2011 Nov;23(6):530-5
pubmed: 21825998
Arthritis Rheumatol. 2015 Apr;67(4):1053-61
pubmed: 25605296
Rheumatology (Oxford). 2015 Aug;54(8):1339-41
pubmed: 26018438
Arthritis Care Res (Hoboken). 2020 Nov;72(11):1625-1635
pubmed: 31539207
BMJ. 2013 Apr 08;346:f1939
pubmed: 23568792
Autoimmun Rev. 2015 Nov;14(11):1019-22
pubmed: 26162302
Rheumatology (Oxford). 2012 Apr;51(4):627-33
pubmed: 22210656